Radioactive gold cluster immunoconjugates: potential agents for cancer therapy

Area of Science:

• Bioconjugation Chemistry
• Nanoparticle-Antibody Conjugates
• Immunology

Background:

• Antibody fragments (Fab', F(ab')2) and whole IgG are crucial for targeted therapies.
• Attaching nanoparticles to antibodies can enhance drug delivery and imaging.
• Maintaining antibody function after conjugation is a significant challenge.

Purpose of the Study:

• To develop a method for covalently attaching undecagold clusters to antibody molecules.
• To evaluate the immunospecificity and immunoreactivity of gold-cluster-labeled antibodies.
• To assess the in vitro and in vivo performance of these conjugates for potential cancer applications.

Main Methods:

• Covalent attachment of 11-gold atom (undecagold) clusters to Fab', F(ab')2, and IgG antibody fragments.
• Characterization of gold-labeled antibodies to determine the number of gold atoms per antibody (11-33).
• In vitro binding assays using 17-1A monoclonal F(ab')2 antibody fragments against human colon carcinoma cells.
• In vivo biodistribution studies of radioactive gold conjugates in nude mice bearing human tumors.

Main Results:

• Undecagold clusters were successfully attached to antibody molecules without significant loss of native immunospecificity.
• Gold cluster-labeled 17-1A monoclonal F(ab')2 antibody fragments retained 80% immunoreactivity in binding to human colon carcinoma cells.
• In vivo biodistribution data for radioactive gold conjugates in tumor-bearing mice were obtained.
• The undecagold labeling strategy allows for a potentially larger destructive payload per antibody.

Conclusions:

• Covalent attachment of undecagold clusters to antibodies is a viable method for creating targeted therapeutic and diagnostic agents.
• The developed conjugates maintain high immunospecificity and immunoreactivity, essential for effective targeting.
• This approach offers potential for enhanced delivery of therapeutic payloads in cancer treatment.